The estimated Net Worth of Lifesciences I, L.P.Clarus ... is at least $54.1 Milión dollars as of 15 June 2015. Lifesciences Clarus owns over 41,230 units of Oxford Immunotec Global PLC stock worth over $49,199,920 and over the last 11 years Lifesciences sold OXFD stock worth over $4,948,450.
Sign up
Lifesciences Clarus OXFD stock SEC Form 4 insiders trading
Lifesciences has made over 6 trades of the Oxford Immunotec Global PLC stock since 2015, according to the Form 4 filled with the SEC. Most recently Lifesciences sold 41,230 units of OXFD stock worth $589,589 on 15 June 2015.
The largest trade Lifesciences's ever made was selling 154,319 units of Oxford Immunotec Global PLC stock on 17 March 2015 worth over $2,260,773. On average, Lifesciences trades about 48,812 units every 13 days since 2013. As of 15 June 2015 Lifesciences still owns at least 2,237,377 units of Oxford Immunotec Global PLC stock.
You can see the complete history of Lifesciences Clarus stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Oxford Immunotec Global PLC
Over the last 11 years, insiders at Oxford Immunotec Global PLC have traded over $13,598,906 worth of Oxford Immunotec Global PLC stock and bought 47,600 units worth $549,576 . The most active insiders traders include James R Tobin, Peter Wrighton Smith a Ronald Asbury Andrews. On average, Oxford Immunotec Global PLC executives and independent directors trade stock every 36 days with the average trade being worth of $536,006. The most recent stock trade was executed by Patrick J Balthrop on 20 May 2020, trading 4,000 units of OXFD stock currently worth $49,920.
What does Oxford Immunotec Global PLC's logo look like?
Complete history of Lifesciences Clarus stock trades at Oxford Immunotec Global PLC
Oxford Immunotec Global PLC executives and stock owners
Oxford Immunotec Global PLC executives and other stock owners filed with the SEC include:
-
Peter Wrighton-Smith,
Chief Executive Officer, Director -
Matthew McLaughlin,
Chief Financial Officer -
Richard Sandberg,
Independent Director -
Patrick Balthrop,
Independent Chairman of the Board -
Herman Rosenman,
Independent Director -
James Tobin,
Independent Director -
Patricia Randall,
Independent Director -
Andrew Walton,
Independent Director -
Mark Klausner,
Independent Director -
Ronald Andrews,
Independent Director -
Janet Kidd,
General Counsel, Company Secretary -
Herm Rosenman,
-
Richard M. Altieri,
Chief Financial Officer -
Peter Edwardson,
Chief Operations Officer -
Stephen L Spotts,
Director -
Jeff R. Schroeder,
Chief Commercial Officer -
Richard Wenstrup,
Chief Medical Officer -
Stefan C Linn,
Chief Operating Officer -
Elizabeth M Keiley,
VP & General Counsel -
Lifesciences I, L.P.Clarus ...,
-
Leaf Ventures Ii, L.P.New L...,